Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program.  Ward KM, Scheim A, Wang J, Cocchiaro B, Singley K, Roth AM.  Drug Alcohol Depend Rep. 2022 Jun;3:100055…

Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.  Hoffman KA, Foot C, Levander XA, Cook R, Terashima JP, McIl…

A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives.  May T, Dawes J, Fancourt D, Burton A.  Int J Drug Policy…

Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic. Alinsky RH, Prichett L, Chang HY, Alexander GC, Stein BD, Saloner B.  J Adolesc Health. 2022 May 8:S1054-139X(22)003…

Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky.  Lei F, Lofwall MR, Freeman PR, Slade E, Vickers-Smith R, Slavova S.  J Rural Health. 2022 May 24. doi: 10.1111…

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic.  Nguyen T, Ziedan E, Simon K, Miles J, Crystal S, Samples H, Gupta S.  JAMA Netw Open. 2022 Jun 1;5(6):e221…